New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2013
12:36 EDTIPXL, SIG, JNS, AGN, AMJHigh option volume; IPXL SIG JNS AGN AMJ
News For IPXL;SIG;JNS;AGN;AMJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 16, 2014
08:58 EDTAGNAllergan was pressured by AbbVie news, says BMO Capital
Subscribe for More Information
07:23 EDTAGNIBF Conferences to hold a summit
Ophthalmology Innovation Summit is being held in Chicago on October 16.
October 15, 2014
15:00 EDTAGNShire-Allergan, AbbVie-Pfizer deals possible if merger scrapped, Bloomberg says
Subscribe for More Information
13:07 EDTAGNAllergan seeing arb-related selling pressure, says BMO Capital
Subscribe for More Information
October 14, 2014
12:55 EDTSIGSignet Jewelers pullback a buying opportunity, says Stephens
Subscribe for More Information
11:00 EDTAMJHigh option volume stocks
High option volume stocks: ABG AMJ SWI CIT INVE VIP PH AMLP CSX DPZ
08:04 EDTSIGSignet Jewelers reaffirms Q2 guidance
Subscribe for More Information
08:03 EDTSIGSignet Jewelers CEO Barnes resigns effective October 31, COO Light to succeed
Subscribe for More Information
06:03 EDTAGNMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
October 13, 2014
10:26 EDTAMJHigh option volume stocks
Subscribe for More Information
08:04 EDTJNSJanus to acquire VelocityShares, includes upfront cash consideration of $30M
Subscribe for More Information
06:39 EDTAGNAllergan takeout value at or above $210 per share, says Leerink
Leerink believes Allergan's takeover value is now at or above $210 per share given the company's recent execution. After speaking with management, the firm says Allergan's upside in Q3 was driving by fundamentals, not cost cuts. It continues to view the "most likely and straightforward outcome" for Allergan as being an outright sale of the company. Leerink raised its price target for shares to $215 from $184 and keeps an Outperform rating on Allergan.
October 10, 2014
17:14 EDTAGNMarket ends week lower amid global growth worries
Subscribe for More Information
10:20 EDTAGNFidelity supports potential merger between Actavis and Allergan, Reuters reports
Subscribe for More Information
10:01 EDTIPXLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:37 EDTAGNActavis more likely partner than Valeant if Allergan merges, says UBS
Subscribe for More Information
07:35 EDTIPXLImpax upgraded to Buy from Hold at WallachBeth
Subscribe for More Information
07:35 EDTAGNAllergan price target raised to $224-$225, from $198-$199 at Wells Fargo
Wells Fargo increased its price target on Allergan after the company pre-released better-than-expected revenue and EPS, and raised its 2014-2016 EPS guidance. The firm keeps an Outperform rating on the shares.
07:16 EDTAGNAmerican Society of Plastic Surgeons to hold annual meeting
Annual Meeting of ASPS is being held in Chicago on October 10-14.
06:58 EDTIPXLImpax upgraded to Buy from Hold at Needham
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use